Triumvira Immunologics today announced that it will present clinical data from its ongoing Phase I/II study investigating the safety and efficacy of autologous TAC-T cells targeting HER2 in relapsed or refractory solid tumors (TACTIC-2 /NCT04727151) at two upcoming scientific conferences.
| AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., Oct. 2, 2023 /PRNewswire/ -- Triumvira Immunologics, Inc., a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will present clinical data from its ongoing Phase I/II study investigating the safety and efficacy of autologous TAC-T cells targeting HER2 in relapsed or refractory solid tumors (TACTIC-2 /NCT04727151) at two upcoming scientific conferences: the European Society for Medical Oncology (ESMO) Congress, being held October 20-24, 2023, in Madrid, Spain, and the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023, in Boston. TAC01-HER2 is a novel cell therapy based on genetically engineered autologous T cells expressing a T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).
Details of the presentation are as follows: ESMO 2023 Congress Title: A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC01-HER2 in Relapsed or Refractory Solid Tumors AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Title: A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors About Triumvira Immunologics Triumvira Immunologics, Inc. (“Triumvira”) is a leading clinical-stage solid tumor cell therapy company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company’s proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. Triumvira is developing a broad pipeline targeting promising tumor-associated antigens such as HER2, Claudin 18.2, GUCY2C and GPC3. Triumvira is headquartered in Austin, Texas, with research facilities in Hamilton, Ontario, and GMP manufacturing facilities in South San Francisco, California. Media Contact David Schull or Ignacio Guerrero-Ros, Ph.D.
SOURCE Triumvira Immunologics |
View original content to download multimedia:
